Gene expression in oligodendroglial tumors

Cellular Oncology

Volumn 34, Issue 4, 2011, Pages 355-367

  Shaw, Elisabeth J ^a   Haylock, Brian ^b   Husband, David ^b   Du Plessis, Daniel ^c   Sibson, D Ross ^a   Warnke, Peter C ^d   Walker, Carol ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemosensitivity; Gene expression; Oligodendroglioma

Indexed keywords

C MYC BINDING PROTEIN; CELL NUCLEUS RECEPTOR; COMPLEMENTARY RNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; INHIBITOR OF DIFFERENTIATION 3; INTERNEXIN NEURONAL INTERMEDIATE FILAMENT PROTEIN ALPHA; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; LEUKOTRIENE B4 RECEPTOR; LOMUSTINE; NUCLEAR RECEPTOR NR2F2; POLY A SPECIFIC RIBONUCLEASE; PROCARBAZINE; PROTEIN; RAS DEXAMETHASONE INDUCED 1 PROTEIN; RIBONUCLEASE; SEPRASE; SINGLE STRANDED DNA BINDING PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA INDUCED FACTOR 1; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER STAGING; CHROMOSOME 1P; CHROMOSOME LOSS; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEREOTACTIC BIOPSY; ALLELIC IMBALANCE; CHROMOSOME 1; CHROMOSOME 19; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; REPRODUCIBILITY; TREATMENT OUTCOME; TUMOR GENE;

ADULT; AGED; ALLELIC IMBALANCE; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PRINCIPAL COMPONENT ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860286154     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0036-6     Document Type: Article

References (50)

1. N. Ariga, E. Sato, N. Ohuchi, H. Nagura, H. Ohtani, Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer. 95, 67-72 (2001)
2. J.G. Cairncross, K. Ueki, M.C. Zlatescu, D.K. Lisle, D.M. Finkelstein, R.R. Hammond, J.S. Silver, P.C. Stark, D.R. Macdonald, Y. Ino, D.A. Ramsay, D.N. Louis, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473-1479 (1998) (Pubitemid 28482012)
3. H.Y. Cheng, H. Dziema, J. Papp, D.P. Mathur, M. Koletar, M.R. Ralph, J.M. Penninger, K. Obrietan, The molecular gatekeeper Dexras1 sculpts the photic responsiveness of the mammalian circadian clock. J. Neurosci. 26, 12984-12995 (2006) (Pubitemid 44954617)
4. S.J. Cleator, T.J. Powles, T. Dexter, L. Fulford, A. Mackay, I.E. Smith, H. Valgeirsson, A. Ashworth, M. Dowsett, The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res. 8, R32 (2006)
5. S. Draghici, P. Khatri, P. Bhavsar, A. Shah, S.A. Krawetz, M.A. Tainsky, Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res. 31, 3775-3781 (2003) (Pubitemid 37442244)
6. F. Ducray, A. Idbaih, A. de Reynies, I. Bieche, J. Thillet, K. Mokhtari, S. Lair, Y. Marie, S. Paris, M. Vidaud, K. Hoang-Xuan, O. Delattre, J.Y. Delattre, M. Sanson, Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol. Cancer. 7, 41 (2008)
7. P.J. French, S.M. Swagemakers, J.H. Nagel, M.C. Kouwenhoven, E. Brouwer, P. van der Spek, T.M. Luider, J.M. Kros, M.J. van den Bent, P.A. Sillevis Smitt, Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 65, 11335-11344 (2005) (Pubitemid 41821690)
8. E.M. Grasbon-Frodl, F.W. Kreth, M. Ruiter, O. Schnell, K. Bise, J. Felsberg, G. Reifenberger, J.C. Tonn, H.A. Kretzschmar, Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer. 121, 2458-2464 (2007) (Pubitemid 350022415)
9. C. Hartmann, W. Mueller, A. von Deimling, Pathology and molecular genetics of oligodendroglial tumors. J. Mol. Med. 82, 638-655 (2004) (Pubitemid 39468489)
10. L.R. Henry, H.O. Lee, J.S. Lee, A. Klein-Szanto, P. Watts, E.A. Ross, W.T. Chen, J.D. Cheng, Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 13, 1736-1741 (2007) (Pubitemid 46952939)
11. H. Huang, Y. Okamoto, H. Yokoo, F.L. Heppner, A. Vital, M. Fevre-Montange, A. Jouvet, Y. Yonekawa, E.N. Lazaridis, P. Kleihues, H. Ohgaki, Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene. 23, 6012-6022 (2004) (Pubitemid 39093547)
12. A. Idbaih, Y. Marie, G. Pierron, C. Brennetot, K. Hoang-Xuan, M. Kujas, K. Mokhtari,M. Sanson, J. Lejeune, A. Aurias, O. Delattre, J. Y. Delattre, Two types of chromosome 1p losses with opposite significance in gliomas. Ann. Neurol. 58, 483-487 (2005) (Pubitemid 41266639)
13. Y. Ino, R.A. Betensky, M.C. Zlatescu, H. Sasaki, D.R. Macdonald, A.O. Stemmer-Rachamimov, D.A. Ramsay, J.G. Cairncross, D.N. Louis, Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin. Cancer Res. 7, 839-845 (2001) (Pubitemid 32708719)
14. M.D. Jenkinson, D.G. du Plessis, T.S. Smith, K.A. Joyce, P.C. Warnke, C. Walker, Histological growth patterns and genotype in oligodendroglial tumours: Correlation with MRI features. Brain. 129, 1884-1891 (2006) (Pubitemid 43999419)
15. T. Kelly, Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updat. 8, 51-58 (2005) (Pubitemid 40797956)
16. J.H. Kim, J.H. Shin, I.H. Kim, Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174-1180 (2004) (Pubitemid 38834312)
17. V.A. Levin, M.S. Edwards, D.C. Wright, M.L. Seager, T.P. Schimberg, J.J. Townsend, C.B. Wilson, Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat. Rep. 64, 237-244 (1980)
18. Y. Liang, M. Diehn, N. Watson, A.W. Bollen, K.D. Aldape, M.K. Nicholas, K.R. Lamborn, M.S. Berger, D. Botstein, P.O. Brown, M.A. Israel, Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl Acad. Sci. U.S.A. 102, 5814-5819 (2005) (Pubitemid 40559642)
19. J.W. Lindsey, Dexamethasone-induced Ras-related protein 1 is a potential regulatory protein in B lymphocytes. Int. Immunol. 19, 583-590 (2007) (Pubitemid 47072202)
20. K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C (T)) Method. Methods. 25, 402-408 (2001) (Pubitemid 34164012)
21. Z. Lwin, H.K. Gan, W.P. Mason, Low-grade oligodendroglioma: Current treatments and future hopes. Expert Rev. Anticancer Ther. 9, 1651-1661 (2009)
22. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr., J.G. Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990) (Pubitemid 20195640)
23. R. Mehrian Shai, J.K. Reichardt, H. Ya-Hsuan, T.J. Kremen, L. M. Liau, T.F. Cloughesy, P.S. Mischel, S.F. Nelson, Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res. Mol. Brain Res. 136, 99-103 (2005) (Pubitemid 40704613)
24. P.S. Mischel, R. Shai, T. Shi, S. Horvath, K.V. Lu, G. Choe, D. Seligson, T.J. Kremen, A. Palotie, L.M. Liau, T.F. Cloughesy, S.F. Nelson, Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 22, 2361-2373 (2003) (Pubitemid 36566791)
25. A. Mukasa, K. Ueki, S. Matsumoto, S. Tsutsumi, R. Nishikawa, T. Fujimaki, A. Asai, T. Kirino, H. Aburatani, Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene. 21, 3961-3968 (2002) (Pubitemid 34679237)
26. J. Pramana, N. Pimentel, I. Hofland, L.F. Wessels, M.L. van Velthuysen, D. Atsma, C.R. Rasch, M.W. van den Brekel, A.C. Begg, Heterogeneity of gene expression profiles in head and neck cancer. Head Neck. 29, 1083-1089 (2007)
27. T. Ramirez-Montagut, N.E. Blachere, E.V. Sviderskaya, D.C. Bennett, W.J. Rettig, P. Garin-Chesa, A.N. Houghton, FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene. 23, 5435-5446 (2004) (Pubitemid 39044054)
28. G. Reifenberger, D.N. Louis, Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62, 111-126 (2003) (Pubitemid 36176946)
29. T. Rikimaru, A. Taketomi, Y. Yamashita, K. Shirabe, T. Hamatsu, M. Shimada, Y. Maehara, Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 72, 69-74 (2007) (Pubitemid 350249132)
30. N. Sanai, M.S. Berger, Glioma extent of resection and its impact on patient outcome. Neurosurgery. 62, 753-764 (2008). discussion 264-756
31. B.W. Scheithauer, G.N. Fuller, S.R. VandenBerg, The 2007 WHO classification of tumors of the nervous system: Controversies in surgical neuropathology. Brain Pathol. 18, 307-316 (2008) (Pubitemid 351784464)
32. R. Shai, T. Shi, T.J. Kremen, S. Horvath, L.M. Liau, T.F. Cloughesy, P.S. Mischel, S.F. Nelson, Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22, 4918-4923 (2003) (Pubitemid 36981282)
33. J. Stremenova, E. Krepela, V. Mares, J. Trim, V. Dbaly, J. Marek, Z. Vanickova, V. Lisa, C. Yea, A. Sedo, Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int. J. Oncol. 31, 785-792 (2007)
34. T. Taira, J. Maeda, T. Onishi, H. Kitaura, S. Yoshida, H. Kato, M. Ikeda, K. Tamai, S.M. Iguchi-Ariga, H. Ariga, AMY-1, a novel CMYC binding protein that stimulates transcription activity of CMYC. Genes Cells. 3, 549-565 (1998) (Pubitemid 28475324)
35. B. Tews, J. Felsberg, C. Hartmann, A. Kunitz, M. Hahn, G. Toedt, K. Neben, L. Hummerich, A. von Deimling, G. Reifenberger, P. Lichter, Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int. J. Cancer. 119, 792-800 (2006) (Pubitemid 44051441)
36. J. Tilgner, M. Herr, C. Ostertag, B. Volk, Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: Intraoperative versus final diagnosis -influence of clinical factors. Neurosurgery 56, 257-265 (2005). discussion 257-265
37. V.G. Tusher, R. Tibshirani, G. Chu, Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. U.S.A. 98, 5116-5121 (2001) (Pubitemid 32397092)
38. G. Vaidyanathan, M.J. Cismowski, G. Wang, T.S. Vincent, K.D. Brown, S.M. Lanier, The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene. 23, 5858-5863 (2004) (Pubitemid 39093032)
39. M.J. van den Bent, A.F. Carpentier, A.A. Brandes, M. Sanson, M.J. Taphoorn, H.J. Bernsen, M. Frenay, C.C. Tijssen, W. Grisold, L. Sipos, H. Haaxma-Reiche, J.M. Kros, M.C. van Kouwenhoven, C.J. Vecht, A. Allgeier, D. Lacombe, T. Gorlia, Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715-2722 (2006) (Pubitemid 46630567)
40. M.J. van den Bent, L.H. Looijenga, K. Langenberg, W. Dinjens, W. Graveland, L. Uytdewilligen, P.A. Sillevis Smitt, R.B. Jenkins, J.M. Kros, Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 97, 1276-1284 (2003) (Pubitemid 36237315)
41. M.J. Van den Bent,M. Reni, G. Gatta, C. Vecht, Oligodendroglioma. Crit. Rev. Oncol. Hematol. 66, 262-272 (2008)
42. D.A. Vandeputte, D. Troost, S. Leenstra, H. Ijlst-Keizers, M. Ramkema, D.A. Bosch, F. Baas, N.K. Das, E. Aronica, Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia. 38, 329-338 (2002)
43. C. Walker, D.G. du Plessis, K.A. Joyce, D. Fildes, A. Gee, B. Haylock, D. Husband, T. Smith, J. Broome, P.C. Warnke, Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann. Neurol. 57, 855-865 (2005) (Pubitemid 40798624)
44. C. Walker, D.G. du Plessis, K.A. Joyce, Y. Machell, J. Thomson-Hehir, S.A. Al Haddad, J.C. Broome, P.C.Warnke, Phenotype versus genotype in gliomas displaying inter-or intratumoral histological heterogeneity. Clin. Cancer Res. 9, 4841-4851 (2003) (Pubitemid 37323288)
45. C. Walker, B. Haylock, D. Husband, K.A. Joyce, D. Fildes, M.D. Jenkinson, T. Smith, J. Broome, D.G. du Plessis, P.C. Warnke, Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology. 66, 1661-1667 (2006) (Pubitemid 43964619)
46. M.A.Watson, A. Perry, V. Budhjara, C. Hicks,W.D. Shannon, K.M. Rich, Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res. 61, 1825-1829 (2001) (Pubitemid 32691992)
47. B. Wiesenhofer, G. Stockhammer, H. Kostron, H. Maier, H. Hinterhuber, C. Humpel, Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol. 99, 131-137 (2000) (Pubitemid 30093419)
48. R. Yamanaka, T. Arao, N. Yajima, N. Tsuchiya, J. Homma, R. Tanaka, M. Sano, A. Oide, M. Sekijima, K. Nishio, Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene. 25, 5994-6002 (2006) (Pubitemid 44477293)
49. S. Yip, A.J. Iafrate, D.N. Louis, Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers. J. Neuropathol. Exp. Neurol. 67, 1-15 (2008)
50. M.Z. Zhang, Y.H. Qiao, J.M. Nesland, Z.H. Suo, Expression of seprase in effusions from patients with epithelial ovarian carcinoma. Chin. Med. J. (Engl) 120, 663-668 (2007) (Pubitemid 46767800)